Today: 9 June 2026
IREN stock jumps 13% as bitcoin hovers near $91,000 — what investors watch next

IREN stock jumps 13% as bitcoin hovers near $91,000 — what investors watch next

NEW YORK, January 4, 2026, 07:29 ET — Market closed.

  • IREN shares jumped 13% in the last session, closing at $42.70.
  • Bitcoin was last near $91,000 in weekend trading, keeping crypto-linked stocks in focus.
  • A new SEC filing registered shares for employee awards as traders brace for key U.S. data next week.

Shares of IREN Ltd (IREN) closed up 13% on Friday at $42.70, giving the crypto-linked stock a strong start to 2026. The Nasdaq-listed shares swung between $38.10 and $42.99, with about 30.5 million shares changing hands.

Bitcoin, the world’s biggest cryptocurrency, was last trading around $91,285 on Sunday, up about 1.8% from its prior close. Moves in bitcoin often spill into U.S.-listed miners and infrastructure providers tied to the token’s price.

Risk-sensitive stocks have been searching for a catalyst as investors look ahead to fresh U.S. economic signals. “The market is looking for direction,” said Matthew Maley, chief market strategist at Miller Tabak, pointing to the monthly jobs report due on Jan. 9 and consumer price data expected on Jan. 13. Reuters

Other U.S.-listed bitcoin miners rallied in sympathy on Friday. Marathon Digital rose about 10%, Riot Platforms gained nearly 12% and CleanSpark jumped about 14%.

IREN has been a volatile proxy for two trades that often move together: crypto sentiment and demand for power-hungry data centers used to train artificial intelligence models.

A regulatory filing added another point for traders to parse. In a Form S-8 filed on Jan. 2, IREN registered 17.5 million ordinary shares for future issuance under its 2025 Omnibus Incentive Plan, which shareholders approved at the company’s annual meeting in November.

An S-8 is typically used to register shares that may be issued to employees under compensation plans. It does not mean the shares are being sold immediately, but it can flag potential dilution over time if awards are granted and exercised.

The filing comes as investors keep a close eye on IREN’s push into AI infrastructure. The company said in a November filing it struck a five-year agreement to provide Microsoft access to dedicated graphics processing unit (GPU) capacity at its Horizon data center facilities in Childress, Texas, with a total contract value of about $9.7 billion through 2031.

IREN also disclosed a related purchase agreement under which Dell Marketing would supply GPUs and related products and services, with deliveries slated to begin in tranches from March 2026. The company said copies of the Microsoft and Dell agreements would be filed as exhibits to its quarterly report for the quarter ended Dec. 31, 2025.

Before the next session, traders are likely to focus on whether bitcoin holds recent gains through the weekend. Crypto trades around the clock, while U.S. equities reopen on Monday, often forcing miner and infrastructure stocks to “catch up” at the open.

Macro data is also a near-term risk for high-beta names. A sharp surprise in jobs or inflation can shift expectations for Federal Reserve policy and move risk assets broadly, including crypto-linked shares.

For IREN, the next major company-specific checkpoint is its next results update. Market calendars tracked by Stock Analysis list Feb. 11, 2026 as the next earnings date, though the company has not confirmed a schedule.

Stock Market Today

  • Proxy Adviser Supports Nanoco Group's Plan to Delist from LSE
    June 9, 2026, 9:17 AM EDT. Nanoco Group PLC, a nanotechnology firm, announced that independent proxy adviser Glass Lewis has recommended shareholders approve the company's resolution to delist from the London Stock Exchange (LSE). The move signals a significant shift for Nanoco, potentially changing its trading and regulatory environment. Shareholder approval for such a resolution typically permits a company to withdraw its shares from public exchange trading, often to pursue private ownership or alternative funding routes. This development follows Nanoco's strategic review and may impact investor access and share liquidity. The recommendation by Glass Lewis adds weight to the proposal ahead of the upcoming shareholder vote.

Latest articles

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

9 June 2026
Factorial Energy surged 16% to $13.80 in its Nasdaq debut as FAC, with premarket trading near $20.70, after replacing CGCT via SPAC merger that raised over $100 million for battery commercialization and implied a $1.3 billion equity value; former CGCT shares now trade as FAC, with founders retaining majority voting power and staged lock-up releases ahead.
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

9 June 2026
Pfizer shares fell 1.7% premarket to $25.62 as investors weighed an FDA label expansion for hemophilia drug Hympavzi—now the first subcutaneous non-factor therapy for children 6-11 with hemophilia B—against slower progress in obesity drugs, with mid-stage data for weight-loss shot berobenatide showing a 23.3% vomiting rate and no immediate growth catalyst for the $147 billion company.
Snap Shares Fall Even as Nasdaq Gains; June 16 in Focus

Snap Shares Fall Even as Nasdaq Gains; June 16 in Focus

9 June 2026
Snap Inc. shares fell 1.9% to $5.65, underperforming a rising Nasdaq and leaving the stock 46% below its 52-week high, as investors weigh weak ad revenue growth, North American user declines, and cost-cutting moves against ongoing competitive pressure from Meta and TikTok.
RIOT stock jumps after Riot Platforms names new CFO and ties bonuses to data-center deals
Previous Story

RIOT stock jumps after Riot Platforms names new CFO and ties bonuses to data-center deals

Tesco issues urgent “do not eat” recall for three pate lines after date-label error
Next Story

Tesco issues urgent “do not eat” recall for three pate lines after date-label error

Go toTop